Oxurion NV
XBRU:OXUR

Watchlist Manager
Oxurion NV Logo
Oxurion NV
XBRU:OXUR
Watchlist
Price: 0.28 EUR Market Closed
Market Cap: 374.2k EUR
Have any thoughts about
Oxurion NV?
Write Note

Operating Margin
Oxurion NV

-8 770.2%
Current
-3 935%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-8 770.2%
=
Operating Profit
-7.4m
/
Revenue
84k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
BE
Oxurion NV
XBRU:OXUR
343.7k EUR
-8 770%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
320.1B USD
28%
US
Amgen Inc
NASDAQ:AMGN
150.5B USD
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
40%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.5B EUR
-22%
Country BE
Market Cap 343.7k EUR
Operating Margin
-8 770%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 320.1B USD
Operating Margin
28%
Country US
Market Cap 150.5B USD
Operating Margin
19%
Country US
Market Cap 120.4B USD
Operating Margin
40%
Country US
Market Cap 113.8B USD
Operating Margin
38%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.4B AUD
Operating Margin
26%
Country US
Market Cap 82.9B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 34.5B EUR
Operating Margin
-22%
No Stocks Found

Oxurion NV
Glance View

Market Cap
343.7k EUR
Industry
Biotechnology

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.

OXUR Intrinsic Value
0.78 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-8 770.2%
=
Operating Profit
-7.4m
/
Revenue
84k
What is the Operating Margin of Oxurion NV?

Based on Oxurion NV's most recent financial statements, the company has Operating Margin of -8 770.2%.